Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 14:10:1134939.
doi: 10.3389/fmed.2023.1134939. eCollection 2023.

Practical aspects of the diagnosis and management of pyoderma gangrenosum

Affiliations
Review

Practical aspects of the diagnosis and management of pyoderma gangrenosum

Bo Chen et al. Front Med (Lausanne). .

Abstract

Pyoderma gangrenosum (PG) is a rare autoinflammatory ulcerative neutrophilic skin disease. Its clinical presentation is a rapidly progressing painful skin ulcer with ill-defined borders and surrounding erythema. The pathogenesis of PG is complex and not fully understood. Clinically, patients with PG often have various systemic diseases, the most common being inflammatory bowel disease (IBD) and arthritis. Due to the lack of specific biological markers, diagnosing PG remains difficult, which easily resulting in misdiagnosis. Some validated diagnostic criteria have been applied in clinical practice that facilitate its diagnosis. The treatment of PG currently consists mainly of immunosuppressive and immunomodulatory agents, especially biological agents, which have bright prospects for PG therapy. After the systemic inflammatory response is controlled, the problem of wounds becomes the main contradiction in PG treatment. Surgery is not controversial for PG, increasing evidence shows that with adequate systemic treatment, the benefits of reconstructive surgery for patients are increasing.

Keywords: chronic wounds; pyoderma gangrenosum; surgery; ulcer; wound healing.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Ruocco E, Sangiuliano S, Gravina A, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol. (2009) 23:1008–17. 10.1111/j.1468-3083.2009.03199.x - DOI - PubMed
    1. Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol. (2012) 13:191–211. 10.2165/11595240-000000000-00000 - DOI - PubMed
    1. Hobbs M, Ortega-Loayza A. Pyoderma gangrenosum: from historical perspectives to emerging investigations. Int Wound J. (2020) 17:1255–65. 10.1111/iwj.13389 - DOI - PMC - PubMed
    1. Marzano A, Borghi A, Wallach D, Cugno M. A comprehensive review of neutrophilic diseases. Clin Rev Allergy Immunol. (2018) 54:114–30. - PubMed
    1. Adachi Y, Kindzelskii A, Cookingham G, Shaya S, Moore E, Todd R, et al. Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol. (1998) 111:259–68. 10.1046/j.1523-1747.1998.00311.x - DOI - PubMed

LinkOut - more resources